Table 6 Panobinostat-based combination in relapsed/refractory multiple myeloma patients
Carfilzomib-panobinostat Kaufman | Panobinostat-bortezomib-dexamethasone San-Miguel14 | Panobinostat-lenalidomide-dexamethasone Chari25 | ||
|---|---|---|---|---|
Panobinostat schedule | 20 mg TIW, 3 weeks on/1 week off | 30 mg TIW, 1 week on/1 week off | 20 mg TIW, 2 weeks on/1 week off | 20 mg TIW, 3 weeks on/1 week off |
Prior regimens, no. | 4 | 5 | 5 | 3 |
Bortezomib refractory patients | 53% | 36% | 100% | 52% |
Lenalidomide refractory patients | 31% | 14%a | NA | 81% |
Bortezomib and lenalidomide refractory patients | 25% | NA | NA | NA |
ORR | 63% | 63% | 34.5% | 41% |
PFS | 8 | 8 | 5 | 7 |
Thrombocytopenia G3–4 | 41% | 38% | 64% | 31% |
Fatigue G3–4 | 18% | 11% | 20% | 15% |
Diarrhea G3–4 | 6% | 11% | 20% | 11% |
Nausea/vomiting G3–4 | 12% | 21% | 18% | 0% |
Discontinuation for toxicity | 19% | 11% | 18% | NA |
Dose reduction for toxicity | 43% | 59% | 65% | 41% |
